Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
Ella Daly(Janssen (Belgium)), Wayne C. Drevets(Johnson & Johnson (United States)), Michael E. Thase(Veterans Health Administration), Luc Van Nueten(Janssen (Belgium)), Pilar Lim(Janssen (Belgium)), Richard C. Shelton(University of Alabama at Birmingham), Husseini K. Manji(National Institutes of Health), Kimberly Cooper(Janssen (Belgium)), Andrew Winokur, Maggie Fedgchin(Janssen (United States)), Jaskaran Singh(Neurocrine Biosciences (United States))
Cited by 712
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Subgenual prefrontal cortex abnormalities in mood disorders
|Nature|1997|2.7k
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression
|Brain Structure and Function|2008|2.2k
Neurocircuitry of Mood Disorders
|Neuropsychopharmacology|2009|1.6k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k